ARTICLE | Clinical News
Bavituximab: Phase III discontinued
March 7, 2016 8:00 AM UTC
Peregrine discontinued the double-blind, international Phase III SUNRISE trial in about 582 previously treated patients with stage IIIb/IV non-squamous NSCLC after a pre-specified interim analysis by ...